DX2400 / Takeda, Sanofi - LARVOL DELTA

Membrane-type 1 matrix metalloproteinase controls the release of algesic myelin basic protein epitopes and pain after constriction nerve injury (Neuroscience 2016) - "Inhibition of MT1-MMP activity, using the selective, function-blocking human DX2400 monoclonal antibody, administered once into the sciatic nerve at day 3 post-CCI, attenuated mechanical allodynia. Finally, we confirmed our earlier in vitro findings that MT1-MMP liberated the 69-86 MBP fragments from the intact MBP, and in vivo observations that the MBP69-86 peptide (rat sequence) injection into the intact nerve was sufficient to produce a robust and lasting state of allodynia. These data implicate MT1-MMP as a key protease in sustaining MBP-induced pain and an important therapeutic target in painful neuropathy."

Preclinical • Biosimilar • Demo Pain • Gene Therapies • Pain